Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
The Effect of Vitagnus on Cyclic Breast Pain in Women of Reproductive Age



Mirmolaei ST1 ; Olfatbakhsh A2 ; Fallahhosseini H3 ; Lili EK4 ; Moridani AS5
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Midwifery, Faculty of Nursing and Midwifery, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Breast Cancer Research Center, Tehran Academic Center for Education, Culture and Research, Tehran, Iran
  3. 3. Medicinal Plant Research Center, Institute of Medicinal Plants, Karaj Academic Center for Education, Culture and Research, Karaj, Iran
  4. 4. Department of Biostatistics and Epidemiology, Guilan University of Medical Sciences, Rasht, Iran
  5. 5. Shahid Beheshti Hospital of Bandar-e Anzali, Guilan University of Medical Sciences, Rasht, Iran

Source: Journal of Babol University of Medical Sciences Published:2016

Abstract

BACKGROUND AND OBJECTIVE: One of the most common complaints in women is breast pain associated with reduced women quality of life and a lot of problems and costs. This study aimed to investigate the effect of vitagnus on severity of cyclic mastalgia in women of reproductive age. METHODS: This study is a triple blind controlled clinical trial performed on 67 women with cyclic mastalgia. Women randomly entered to an intervention group (34 patients) or a placebo (n=33) groups and training and proper nutrition were done. Vitagnus daily was given for three months in the intervention group (8 ml) and eatable paraffin (1 ml) mixed with water and honey (a total of 10 ml) was given to the placebo group. The pain from two months before to three months after treatment with VAS and McGill measuring instruments were compared. FINDINGS: The mean score of McGill in Vitagnus group decreased from 16.94±3.94 before the intervention to 9.50±5.32 in fifth month and in the placebo group decreased from 15.08±3.62 before the intervention to 13.08±4.29 in fifth month (p<0.0001). Mean VAS score in Vitagnus Group decreased from 6.59±3.35 before the intervention to 3.27±2.20 in fifth month and in the placebo group from 5.94±1.32 before the intervention to 4.94±1.81 in the fifth month (p<0.0001). CONCLUSION: The results showed that Vitagnus can be used as an effective and low-cost treatment in the treatment of mastalgia. © 2016, Babol University of Medical Sciences. All rights reserved.